 Kenneth Malcolm
Concepts (316)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium abscessus | 12 | 2026 | 110 | 4.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 17 | 2026 | 339 | 3.260 |
Why?
| | Neutrophils | 30 | 2025 | 1127 | 2.650 |
Why?
| | Host-Pathogen Interactions | 4 | 2025 | 361 | 1.710 |
Why?
| | Cystic Fibrosis | 17 | 2026 | 1163 | 1.630 |
Why?
| | Phagocytosis | 8 | 2026 | 296 | 1.090 |
Why?
| | Azithromycin | 4 | 2020 | 101 | 0.830 |
Why?
| | Immunity, Humoral | 1 | 2025 | 118 | 0.820 |
Why?
| | Interferons | 2 | 2016 | 186 | 0.750 |
Why?
| | Lipopolysaccharides | 11 | 2025 | 858 | 0.730 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 2601 | 0.680 |
Why?
| | Immunity, Innate | 3 | 2025 | 835 | 0.620 |
Why?
| | Anti-Bacterial Agents | 12 | 2026 | 1925 | 0.600 |
Why?
| | Klebsiella pneumoniae | 2 | 2018 | 47 | 0.580 |
Why?
| | Pseudomonas aeruginosa | 9 | 2026 | 397 | 0.580 |
Why?
| | Pseudomonas | 1 | 2018 | 30 | 0.570 |
Why?
| | Fomites | 1 | 2017 | 6 | 0.530 |
Why?
| | Nontuberculous Mycobacteria | 7 | 2025 | 189 | 0.520 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 224 | 0.520 |
Why?
| | Tobramycin | 5 | 2026 | 63 | 0.430 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2004 | 288 | 0.390 |
Why?
| | Pseudomonas Infections | 5 | 2022 | 231 | 0.380 |
Why?
| | Myelodysplastic Syndromes | 2 | 2026 | 165 | 0.370 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.370 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.370 |
Why?
| | Reactive Oxygen Species | 4 | 2020 | 611 | 0.370 |
Why?
| | Bacteria | 1 | 2018 | 766 | 0.350 |
Why?
| | Staphylococcus aureus | 3 | 2015 | 454 | 0.350 |
Why?
| | Mycobacterium | 1 | 2013 | 101 | 0.350 |
Why?
| | Superoxides | 5 | 2018 | 198 | 0.340 |
Why?
| | Sputum | 5 | 2025 | 302 | 0.320 |
Why?
| | Microbial Viability | 3 | 2018 | 83 | 0.300 |
Why?
| | Immunoglobulin G | 2 | 2025 | 892 | 0.290 |
Why?
| | Biofilms | 5 | 2014 | 292 | 0.270 |
Why?
| | Extracellular Traps | 2 | 2018 | 52 | 0.260 |
Why?
| | Macrophages | 6 | 2026 | 1507 | 0.260 |
Why?
| | Humans | 47 | 2026 | 145783 | 0.240 |
Why?
| | Immunoglobulin M | 2 | 2025 | 265 | 0.240 |
Why?
| | Interleukin-8 | 3 | 2020 | 269 | 0.240 |
Why?
| | Mannose-Binding Lectin | 1 | 2025 | 20 | 0.220 |
Why?
| | Phage Therapy | 1 | 2025 | 17 | 0.220 |
Why?
| | Extracellular Space | 2 | 2018 | 117 | 0.210 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1777 | 0.210 |
Why?
| | Cell Separation | 3 | 2016 | 306 | 0.210 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2002 | 751 | 0.210 |
Why?
| | Antibodies, Bacterial | 1 | 2025 | 147 | 0.210 |
Why?
| | Complement C3 | 1 | 2025 | 187 | 0.200 |
Why?
| | Toll-Like Receptors | 3 | 2017 | 193 | 0.180 |
Why?
| | Cytokines | 8 | 2018 | 2069 | 0.180 |
Why?
| | GTP-Binding Proteins | 1 | 2003 | 153 | 0.180 |
Why?
| | Antimalarials | 1 | 2022 | 35 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 7 | 2011 | 264 | 0.180 |
Why?
| | Primary Cell Culture | 2 | 2020 | 172 | 0.180 |
Why?
| | Complement Activation | 1 | 2025 | 399 | 0.170 |
Why?
| | Disease Models, Animal | 6 | 2026 | 4568 | 0.170 |
Why?
| | Case-Control Studies | 3 | 2020 | 3634 | 0.170 |
Why?
| | Pneumonia, Bacterial | 3 | 2013 | 113 | 0.170 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 31 | 0.160 |
Why?
| | Bacteriophages | 1 | 2022 | 110 | 0.160 |
Why?
| | Chloroquine | 1 | 2020 | 54 | 0.160 |
Why?
| | RNA Splicing | 2 | 2023 | 284 | 0.160 |
Why?
| | Bacterial Proteins | 1 | 2026 | 968 | 0.150 |
Why?
| | Mice | 16 | 2026 | 18355 | 0.150 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 318 | 0.150 |
Why?
| | Sirolimus | 1 | 2020 | 282 | 0.140 |
Why?
| | Transcription Factors | 1 | 2026 | 1736 | 0.140 |
Why?
| | Intracellular Space | 1 | 2018 | 64 | 0.130 |
Why?
| | Autophagy | 1 | 2020 | 291 | 0.130 |
Why?
| | Respiratory System | 1 | 2018 | 150 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 426 | 0.130 |
Why?
| | Lung | 9 | 2024 | 4116 | 0.130 |
Why?
| | Aztreonam | 1 | 2016 | 11 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2003 | 769 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 688 | 0.120 |
Why?
| | Signal Transduction | 3 | 2020 | 5224 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 423 | 0.110 |
Why?
| | Survival Analysis | 2 | 2016 | 1378 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 838 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2016 | 193 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2017 | 248 | 0.110 |
Why?
| | Animals | 17 | 2026 | 38101 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 365 | 0.110 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2015 | 81 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2933 | 0.110 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2014 | 49 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 574 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2022 | 2805 | 0.100 |
Why?
| | Oxidants | 1 | 2014 | 99 | 0.100 |
Why?
| | Cell Movement | 4 | 2013 | 963 | 0.100 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.100 |
Why?
| | Phagocytes | 1 | 2014 | 80 | 0.100 |
Why?
| | Deoxyribonucleases | 2 | 2011 | 24 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2014 | 143 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 80 | 0.100 |
Why?
| | Odds Ratio | 1 | 2016 | 1083 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2011 | 1217 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 382 | 0.100 |
Why?
| | Rhinitis | 1 | 2015 | 169 | 0.090 |
Why?
| | Virulence Factors | 1 | 2014 | 175 | 0.090 |
Why?
| | Male | 14 | 2026 | 73010 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1547 | 0.090 |
Why?
| | Prospective Studies | 5 | 2025 | 8078 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 60 | 0.090 |
Why?
| | Sinusitis | 1 | 2015 | 227 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2015 | 529 | 0.090 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2011 | 7 | 0.080 |
Why?
| | Neutrophil Infiltration | 3 | 2013 | 107 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 271 | 0.080 |
Why?
| | Actins | 3 | 2009 | 426 | 0.080 |
Why?
| | Chemokine CXCL5 | 1 | 2011 | 19 | 0.080 |
Why?
| | Cell Lineage | 1 | 2013 | 378 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 298 | 0.080 |
Why?
| | Female | 13 | 2026 | 79045 | 0.080 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 45 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2025 | 11794 | 0.080 |
Why?
| | Interleukin-17 | 1 | 2011 | 120 | 0.080 |
Why?
| | Species Specificity | 1 | 2011 | 546 | 0.080 |
Why?
| | Lipids | 1 | 2015 | 707 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4302 | 0.080 |
Why?
| | Viruses | 1 | 2011 | 166 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 534 | 0.070 |
Why?
| | Retroviridae | 1 | 2008 | 100 | 0.070 |
Why?
| | cdc42 GTP-Binding Protein | 2 | 2006 | 21 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 387 | 0.070 |
Why?
| | Peptides | 2 | 2011 | 999 | 0.070 |
Why?
| | Transgenes | 1 | 2008 | 190 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 993 | 0.070 |
Why?
| | Burns | 1 | 2013 | 374 | 0.070 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 83 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1129 | 0.060 |
Why?
| | Adult | 8 | 2025 | 40881 | 0.060 |
Why?
| | Bone Marrow | 1 | 2008 | 307 | 0.060 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2007 | 45 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2014 | 499 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 956 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2006 | 76 | 0.060 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 125 | 0.060 |
Why?
| | Up-Regulation | 3 | 2006 | 848 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 6033 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 375 | 0.060 |
Why?
| | Middle Aged | 4 | 2020 | 36309 | 0.060 |
Why?
| | Inflammation | 5 | 2022 | 2884 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 322 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 308 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 2 | 2007 | 276 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1437 | 0.050 |
Why?
| | Dinoprostone | 1 | 2005 | 180 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2026 | 335 | 0.050 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1043 | 0.050 |
Why?
| | Transcription, Genetic | 4 | 2008 | 1454 | 0.050 |
Why?
| | Membrane Microdomains | 1 | 2004 | 34 | 0.050 |
Why?
| | Inflammation Mediators | 2 | 2011 | 507 | 0.050 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 32 | 0.050 |
Why?
| | NF-kappa B | 4 | 2013 | 667 | 0.050 |
Why?
| | Enzyme Precursors | 1 | 2003 | 15 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 68 | 0.050 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2026 | 337 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2004 | 91 | 0.050 |
Why?
| | Mutation | 2 | 2026 | 4090 | 0.050 |
Why?
| | Zymosan | 1 | 2023 | 39 | 0.050 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 18 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 413 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 196 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2003 | 13 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | eIF-2 Kinase | 1 | 2003 | 28 | 0.050 |
Why?
| | Bacterial Load | 2 | 2015 | 67 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 14254 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 122 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2003 | 66 | 0.050 |
Why?
| | Enzyme Activation | 4 | 2008 | 762 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 346 | 0.050 |
Why?
| | Escherichia coli | 1 | 2007 | 835 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 66 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2005 | 373 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2026 | 2050 | 0.040 |
Why?
| | Toll-Like Receptor 2 | 1 | 2003 | 125 | 0.040 |
Why?
| | Interferon Type I | 1 | 2003 | 147 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10919 | 0.040 |
Why?
| | Gene Expression | 2 | 2008 | 1478 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 383 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2003 | 206 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2013 | 372 | 0.040 |
Why?
| | Ciprofloxacin | 2 | 2013 | 31 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 267 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 372 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2022 | 571 | 0.040 |
Why?
| | Apoptosis | 2 | 2008 | 2444 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 431 | 0.040 |
Why?
| | Trans-Activators | 1 | 2003 | 396 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 53 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1062 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 3130 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 314 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2002 | 474 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 8347 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 7134 | 0.030 |
Why?
| | British Columbia | 1 | 2018 | 25 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 638 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2191 | 0.030 |
Why?
| | Chemokine CXCL1 | 2 | 2011 | 76 | 0.030 |
Why?
| | Cell Migration Inhibition | 2 | 2011 | 16 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2011 | 115 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 42 | 0.030 |
Why?
| | Imidazoles | 3 | 2002 | 247 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 154 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 1023 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2011 | 5992 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1482 | 0.030 |
Why?
| | Cathelicidins | 1 | 2015 | 40 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 405 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2014 | 32 | 0.030 |
Why?
| | Aged | 2 | 2015 | 26217 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 544 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2123 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1812 | 0.030 |
Why?
| | Gentamicins | 1 | 2015 | 50 | 0.030 |
Why?
| | Enzyme Inhibitors | 3 | 2002 | 821 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2002 | 3418 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1898 | 0.030 |
Why?
| | NADPH Oxidases | 1 | 2014 | 122 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 77 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 185 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2011 | 1368 | 0.020 |
Why?
| | PPAR gamma | 1 | 2014 | 182 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 1797 | 0.020 |
Why?
| | Survival Rate | 1 | 2018 | 2094 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 401 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2003 | 153 | 0.020 |
Why?
| | Spleen | 1 | 2015 | 508 | 0.020 |
Why?
| | Chemokine CCL2 | 2 | 2003 | 112 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2013 | 318 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 247 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 334 | 0.020 |
Why?
| | Fibrinogen | 1 | 2013 | 180 | 0.020 |
Why?
| | Down-Regulation | 2 | 2006 | 618 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 354 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 193 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 539 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 28 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 392 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 41 | 0.020 |
Why?
| | Corneal Ulcer | 1 | 2011 | 20 | 0.020 |
Why?
| | Epithelium, Corneal | 1 | 2011 | 41 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 638 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 979 | 0.020 |
Why?
| | Genome | 1 | 2013 | 305 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 109 | 0.020 |
Why?
| | Methacrylates | 1 | 2011 | 119 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 232 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2865 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 451 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 653 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2823 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4330 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 82 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5428 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2013 | 892 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 88 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4556 | 0.020 |
Why?
| | Pyridines | 2 | 2002 | 609 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 162 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 373 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2011 | 307 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 241 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2007 | 30 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 50 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 126 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 75 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2013 | 2514 | 0.010 |
Why?
| | Keratinocytes | 1 | 2007 | 249 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 115 | 0.010 |
Why?
| | Child | 2 | 2020 | 22740 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 11 | 0.010 |
Why?
| | rac GTP-Binding Proteins | 1 | 2004 | 35 | 0.010 |
Why?
| | Vital Capacity | 1 | 2005 | 292 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 161 | 0.010 |
Why?
| | Syk Kinase | 1 | 2003 | 19 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 29 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 450 | 0.010 |
Why?
| | rho GTP-Binding Proteins | 1 | 2004 | 56 | 0.010 |
Why?
| | Anthracenes | 1 | 2003 | 31 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2004 | 86 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4151 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1247 | 0.010 |
Why?
| | Chemokines | 1 | 2004 | 217 | 0.010 |
Why?
| | Dexamethasone | 1 | 2005 | 365 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5925 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 505 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2004 | 322 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 90 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1300 | 0.010 |
Why?
| | Cholesterol | 1 | 2004 | 408 | 0.010 |
Why?
| | Protein Phosphatase 2 | 1 | 2002 | 41 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 110 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 1104 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 2002 | 81 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 668 | 0.010 |
Why?
| | Aminopyridines | 1 | 2002 | 129 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 143 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2002 | 79 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 478 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2008 | 1134 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2003 | 457 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 782 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22577 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2171 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1049 | 0.010 |
Why?
| | Homeostasis | 1 | 2004 | 644 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2131 | 0.010 |
Why?
| | Proteome | 1 | 2002 | 513 | 0.010 |
Why?
|
|
Malcolm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|